

## Phase II COVID-19 clinical trial initiated to evaluate ABNCoV2 as a booster vaccine

**Hørsholm, Denmark, Aug 23, 2021 – AdaptVac, a PREVENT-nCoV consortium member, announces that a phase II clinical trial to evaluate the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 vaccine has been initiated by Bavarian Nordic. The trial will investigate the potential of ABNCoV2 as a booster vaccine for individuals with previous COVID-19 disease or vaccination. Initial trial results are expected in Q3/Q4 2021.**

The trial will enroll 150 healthy adults with existing immunity against SARS-CoV-2, acquired through previous disease or from immunization with either mRNA or adenovirus-based vaccines, and will investigate the ability of a single vaccination with ABNCoV2 to boost existing levels of SARS-CoV-2 neutralizing antibodies across all groups. A second arm in the trial will enroll up to 60 healthy adults with no prior vaccination or disease who will receive two vaccinations for evaluation of neutralizing antibody levels from ABNCoV2 when used as a prime-boost vaccine. In both groups, neutralizing immune responses against circulating variants of SARS-CoV2 will be evaluated.

*“We are excited to have the ABNCoV2 vaccine progress to a Phase II clinical study. This is another big step towards the goal of delivering a safe and efficacious vaccine to help end the COVID-19 pandemic world-wide.”*, said Wian de Jongh, AdaptVac’s CEO.

For further information about AdaptVac ApS, please contact:

Dr. Wian de Jongh, CEO

Telephone: +45 26394649

E-mail: [wdj@adaptvac.com](mailto:wdj@adaptvac.com)

### **About the PREVENT-nCoV consortium**

The consortium is funded by an EU Horizon 2020 grant to develop a COVID-19 vaccine (Grant agreement 101003608 <https://cordis.europa.eu/project/id/101003608>). Further the vaccine development at University of Copenhagen is supported by the Carlsberg Foundation, the Danish research councils and Gudbjørg og Ejnar Honorés Fond. The consortium members are world-leading experts in their respective fields, covering all relevant areas of viral research and vaccine development required for rapid clinical development of a COVID-19 vaccine. This includes pre-clinical and clinically validated experience from working with similar Coronaviruses such as MERS and SARS, ExpreS<sup>2</sup>ion’s *Drosophila* S2 insect cell expression system, and AdaptVac’s capsid virus-like particle (cVLP) technology. In addition to [ExpreS<sup>2</sup>ion](#) and [AdaptVac](#), the consortium members are Leiden University Medical Center ([LUMC](#)), Institute for Tropical Medicine ([ITM](#)) at University of Tübingen, The Department of Immunology and Microbiology ([ISIM](#)) at University of Copenhagen, the Laboratory of Virology at [Wageningen University](#), and Radboud University Medical Center. Through the Carlsberg foundation grant the Prevent-nCoV consortium works closely together with Department of Biomedicine at Aarhus University.

### **About AdaptVac**

AdaptVac is a joint venture between ExpreS<sup>2</sup>ion Biotechnologies and NextGen Vaccines, owned by the inventors of the novel proprietary and ground-breaking viral capsid-like virus particle (cVLP) platform technology spun out from the University of Copenhagen. The Company aims to accelerate the development of highly efficient therapeutic and prophylactic vaccines within high value segments of oncology, infectious diseases and immunological disorders. Granting of the core patent in the U.S. has expanded AdaptVac’s patent protection to include our entire pipeline of vaccines and immunotherapies in development. Please visit: [www.AdaptVac.com](http://www.AdaptVac.com)

*This press release was submitted for publication through the agency of the contact person set out above on August 23, 2021.*